Nama's AI scorecard currently rates Amneal Pharmaceuticals Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is AMRX's P/E ratio?

Amneal Pharmaceuticals trades at a trailing price-to-earnings ratio of 19.4.

When does AMRX report earnings?

Amneal Pharmaceuticals's next scheduled report is on Feb 26, 2027. Analysts expect EPS of $0.24.

What is the AMRX price target?

The median analyst price target from 7 analysts is $25.00, with a range of $20.00 – $27.00.

Is AMRX Shariah compliant?

Nama's AAOIFI-style screen reads Amneal Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

Amneal Pharmaceuticals (AMRX)

Healthcare · Drug Manufacturers Specialty Generic · NASDAQ

Amneal Pharmaceuticals (AMRX) is a Healthcare company in the Drug Manufacturers Specialty Generic industry. It has a market capitalization of $7.01B, a trailing price-to-earnings ratio of 19.4 and a free-cash-flow yield of 3.4%. Over the most recent reported fiscal year, revenue grew 8.1% and free cash flow per share fell 2.5%. Nama's AI scorecard rates it Sell, 4.1 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 4.1/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +68.5% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-7.1%

How far the last close sits under the highest price of the past five years.

Market cap	$7.01B
Trailing P/E	19.4
Price / book	201.4
Price / sales	2.2
FCF yield	3.4%
Dividend yield	—
Gross margin	39.3%
Operating margin	15.4%
Net margin	5.0%
Revenue growth (YoY)	+8.1%
Revenue growth (3-yr annual)	+10.9%
EPS growth (YoY)	+44.8%
FCF/share growth (YoY)	-2.5%
Beta	1.2
Exchange	NASDAQ
Sector	Healthcare
Industry	Drug Manufacturers Specialty Generic

AMRX earnings

Next report: Feb 26, 2027 (Q4 2026, EPS estimate $0.24). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.26	$0.24	+8.3%	—
Q2 2026	Jul 30, 2026	$0.30	$0.23	+30.4%	$796.20M
Q1 2026	May 7, 2026	$0.27	$0.17	+58.8%	$722.52M
Q4 2025	Feb 27, 2026	$0.21	$0.18	+16.7%	$814.32M

AMRX analyst price target

Median target $25.00 from 7 analysts, ranging $20.00 – $27.00.

Drug Manufacturers Specialty Generic peers

Ticker	Company	Market cap	P/E
TAK	Takeda Pharmaceutical	$67.16B	42.0
TEVA	Teva Pharmaceutical Industries	$49.72B	18.0
HLN	Haleon	$40.17B	21.3
ZTS	Zoetis	$32.81B	12.0
UTHR	United Therapeutics	$23.94B	21.2
VTRS	Viatris	$22.87B	7.8
NBIX	Neurocrine Biosciences	$16.66B	16.5
ELAN	Elanco Animal Health	$12.86B	24.3

Explore live AMRX data on Nama Insights →

AMRX FAQ

Is AMRX a buy?: Nama's AI scorecard currently rates Amneal Pharmaceuticals Sell (4.1 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is AMRX's P/E ratio?: Amneal Pharmaceuticals trades at a trailing price-to-earnings ratio of 19.4.
When does AMRX report earnings?: Amneal Pharmaceuticals's next scheduled report is on Feb 26, 2027. Analysts expect EPS of $0.24.
What is the AMRX price target?: The median analyst price target from 7 analysts is $25.00, with a range of $20.00 – $27.00.
Is AMRX Shariah compliant?: Nama's AAOIFI-style screen reads Amneal Pharmaceuticals as Not Shariah Compliant. At least one of the three ratios or the industry test failed.